The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of the AIO 0307 study: A controlled, randomized, double-blind phase II study of FOLFOX6 or FOLFIRI combined with sorafenib (S) versus placebo (P) in second-line metastatic colorectal carcinoma (mCRC) treatment.
Thomas Hoehler
No relevant relationships to disclose
Thomas Decker
No relevant relationships to disclose
Christoph Schimanski
Research Funding - Bayer
Stephan H. Schmitz
No relevant relationships to disclose
Stephan Kanzler
No relevant relationships to disclose
Jacqueline Rauh
No relevant relationships to disclose
Ursula Vehling-Kaiser
No relevant relationships to disclose
Helga Bernhard
No relevant relationships to disclose
Thomas Hoffmann
No relevant relationships to disclose
Norbert Niederle
No relevant relationships to disclose
Ulla Von Verschuer
No relevant relationships to disclose
Goetz von Wichert
No relevant relationships to disclose
Thomas Wagner
No relevant relationships to disclose